Citi analyst Geoff Meacham initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target The firm believes the company is positioned to launch telitacicept to indications with “significant” unmet medical need, beginning with myasthenia gravis and Sjogren’s disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: